



(12) Translation of
European patent specification

(11) NO/EP 3216793 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/14 (2006.01)
A61K 31/53 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.07.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.03.27
(86)	European Application Nr.	17162947.0
(86)	European Filing Date	2009.05.21
(87)	The European Application's Publication Date	2017.09.13
(30)	Priority	2008.05.23, US, 55661 P
(84)	Designated Contracting States:	AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; TR
	Designated Extension States:	AL BA RS
(62)	Divided application	EP2294072, 2009.05.21
(73)	Proprietor	Wyeth LLC, 235 East 42nd Street, New York, NY 10017-5755, USA
(72)	Inventor	VENKATESAN, Aranapakam M., 97-07 63rd Road, 9K, Rego Park, NY 11374, USA CHEN, Zecheng, 2 Westgate Blvd., New City, NY 10956, USA DEHNHARDT, Christoph M., 423 East 83rd Street, Apt 4E, New York, NY 10128, USA DOS SANTOS, Osvaldo, 35-15 34th Street, Apartment B22, Astoria, NY 11106, USA DELOS SANTOS, Efen Guillermo, 38 Birchwood Terrace, Nanuet, NY 10954, USA ZASK, Arie, 21 East 9th Street, New York, NY 10128, USA VERHEIJEN, Jeroen C., 154 Schunnemunk Road, Highland Mills, NY 10930, USA KAPLAN, Joshua Aaron, 10 High Avenue, Nyack, NY 10960, USA RICHARD, David J., 64 Old Ridge Road, Warwick, NY 10990, USA AYRAL-KALOUSTIAN, Semiramis, 484 Carrollwood Drive, Tarrytown, NY 10591, USA MANSOUR, Tarek S., 5 Overlook Road, New City, NY 10956, USA GOPALSAMY, Ariamala, 21 Whispering Pines Drive, Mahwah, NJ 07430, USA CURRAN, Kevin J., 198 Foltim Way, Congers, NY 10920, USA SHI, Mengxiao, 57 Mill Road, Eastchester, NY 10709, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	TRIAZINE COMPOUNDS AS P13 KINASE AND MTOR INHIBITORS
(56)	References Cited:	EP-A- 1 020 462

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk akseptabelt salt av 1-(4-{[4-(dimetylamino)piperidin-1-yl]karbon}fenyl)-3-[4-(4,6-dimorfolin-4-yl-1,3,5-triazin-2-yl)fenyl]urea, hvori
 5 det farmasøytisk akseptable saltet er valgt fra gruppen bestående av acetat-, aluminium-, amsonat-(4,4-diaminostilben-2,2-disulfonat)-, benzatin-(N,N'-dibenzyletylendiamin)-, benzensulfonat-, benzoat-, bikarbonat-, vismut-, bisulfat-, bitartrat-, borat-, bromid-, butyrat-, kalsium-, kalsiumedetat-, kamsylat-(kamfersulfonat)-, karbonat-, klorid-, kolin-, citrat-, klavulariat-, dietanolamin-,
 10 dihydroklorid-, difosfat-, edetat-, edisylate-(kamfersulfonat)-, esylate(etansulfonat)-, etylendiamin-, fumarat-, gluceptat-(glukoheptonat)-, glukonat-, glukuronat-, glutamat-, heksafluorfosfat-, heksylresorcinat-, hydrabamin-(N,N'-bis(dehydroabietyl)etylendiamin)-, hydrobromid-, hydroklorid-,
 15 hydroksynaftoat-, 1-hydroksy-2-naftoat-, 3-hydroksy-2-naftoat-, jodid-, isotionat (2-hydroksyetansulfonat)-, laktat-, laktobionat-, laurat-, laurylsulfat-, litium-, magnesium-, malat-, maleat-, mandelat-, meglumin-(1-deoksy-1-(metylamino)-D-glucitol)-, mesylat-, mucat-, napsylat-, nitrat-, N-metylglukaminammoniumsalt-, oleat-, oksalat-, palmitat-, pamoat-(4,4'-metylenbis-3-hydroksy-2-naftoat eller embonat)-, pantotenat-, fosfat-, picrat-,
 20 polygalakturonat-, kalium-, propionat-, p-toluensulfonat-, salicylat-, natrium-, stearat-, subacetat-, suksinat-, sulfat-, sulfosaliculat-, suramat-, tannat-, tartrat-, teoklat- (8-klor-3,7-dihydro-1,3-dimetyl-1H-purin-2,6-dion)-, trietjodid, trometamin-(2-amino-2-(hydroksymetyl)-1,3-propanediol)-, valerat- og
 25 sinksalter.

2. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 1 og en farmasøytisk akseptabel bærer.

3. Farmasøytisk sammensetning omfattende en forbindelse ifølge krav 1; en andre
 30 forbindelse valgt fra gruppen bestående av en topoisomerase I-inhibitor, en MEK 1/2-inhibitor, en HSP90-inhibitor, prokarbazin, dakarbazin, gemcitabin, kapecitabin, metotreksat, taxol, taxotere, merkaptopurin, tioguanin, hydroksyurea, cytarabin, syklofosamid, ifosfamid, nitrosoureas, cisplatin, karboplatin, mitomycin, dakarbazin, prokarbizin, etoposid, teniposid,
 35 campatheciner, bleomycin, doksorubicin, idarubicin, daunorubicin, daktinomycin, plikamycin, mitoksantron, L-asparaginase, doksorubicin, epirubicin, 5-fluorouracil, docetaxel, paklitaxel, leucovorin, levamisol, irinotecan, estramustin, etoposid,

nitrogensenneper, BCNU, karmustin, lomustin, vinblastin, vinkristin, vinorelbin, cisplatin, karboplatin, oksaliplatin, imatinib mesylat, Avastin (bevacizumab), heksametylmelamin, topotekan, tyrosinkinaseinhibitorer, tyrfostiner, herbimycin A, genistein, erbstatin, hydroksyzin, glatirameracetat, interferon beta-1a, interferon beta-1b, natalizumab og lavendustin A; og en farmasøytisk akseptabel bærer.

4. Sammensetningen ifølge krav 3, hvori den andre forbindelse er Avastin (bevacizumab).

5. Forbindelse ifølge krav 1 for anvendelse i behandling av en PI3K-relatert lidelse eller en mTOR-relatert lidelse, hvori den PI3K-relaterte lidelsen eller den mTOR-relaterte lidelsen er valgt fra restenose, aterosklerose, benlidelser, artritt, diabetisk retinopati, psoriasis, godartet prostatahypertrofi, aterosklerose, inflammasjon, angiogenese, immunologiske lidelser, pankreatitt, nyresykdom og kreft.

6. Forbindelse for anvendelse ifølge krav 5, hvori den PI3K-relaterte lidelsen eller den m-TOR-relaterte lidelsen er kreft.

7. Forbindelse for anvendelse ifølge krav 6 hvori kreften er valgt fra gruppen bestående av leukemi, hudkreft, blærekreft, brystkreft, livmorskreft, eggstokkreft, prostatakreft, lungekreft, tykktarmskreft, bukspyttkjertelkreft, nyrekreft, gastrisk kreft, hjernekreft, fremskreden nyrecellekarsinom, akutt lymfoblastisk leukemi, akutt malignt melanom og bløtvevs- eller bensarkom.

8. Kombinasjon av en forbindelse ifølge krav 1 og et annet terapeutisk middel for samtidig administrering.